About Myriad

Founded in 1991, Myriad Genetics soon emerged as a world leader in the new field of molecular diagnostics. In addition to its molecular diagnostics business, Myriad has a strong drug development pipeline, Going forward, Myriad is uniquely positioned to develop and commercialize new molecular diagnostics and pharmaceuticals that prevent or mitigate the toll of mankind's deadliest diseases.

Pharmaceuticals

Myriad Pharmaceuticals is an organization with capabilities ranging from the identification of novel drug targets, discovery of lead molecules, development of drug candidates and finally, to designing and executing clinical programs. We believe our strategy is a model for success in the biopharmaceutical industry. We focus on disease areas for which there is a large, unmet medical need and we apply a novel approach to therapeutic development based on new technologies and new ways of looking at drug development problems.

Molecular Diagnostics

We are world leaders in molecular diagnosis of hereditary cancer risk. Our products are used by individuals with a history of cancer in their family to determine their own risk of developing cancer. Risk of cancer may be managed and cancer may be averted through appropriate strategies.Myriad is committed to personalized and predictive medicine. The era of more discreet use of medicines is upon us, one in which patients are screened in advance to determine their best therapeutic choice. We see an explosion in the growth of personalized medicine and intend to continue leading the field through the development and introduction of innovative products.